Disclosed herein is a composition including Lactobacillus plantarum TWK10 deposited at the China General Microbiological Culture Collection Center (CGMCC) under accession number CGMCC 13008 for use in treating sarcopenia and for use in maintaining and/or increasing muscle mass and/or strength in an elderly subject.

Provided are a novel yeast strain producing glutathione and a method of producing glutathione using the same.

An aspect is to provide a prebiotic for growing a butyrate-producing bacterium. A prebiotic composition for a butyrate-producing bacterium includes alginic acid and/or a salt thereof having an average molecular weight of 10000 or less.

An aspect is to provide a prebiotic for growing a butyrate-producing bacterium. A prebiotic composition for a butyrate-producing bacterium includes alginic acid and/or a salt thereof having an average molecular weight of 10000 or less.

The present invention relates to a composition for enhancing or improving immunity comprising a Bifidobacterium bifidum. In addition, it can be used to prevent, treat, or improve immune diseases caused by immunodeficiency, immunosuppression, or immune system damage. It can be provided as a food composition or a pharmaceutical composition, and the food composition can be provided in various forms such as probiotic products, health functional supplements, animal feed, and the like.

The present invention relates to a composition for enhancing or improving immunity comprising a Bifidobacterium bifidum. In addition, it can be used to prevent, treat, or improve immune diseases caused by immunodeficiency, immunosuppression, or immune system damage. It can be provided as a food composition or a pharmaceutical composition, and the food composition can be provided in various forms such as probiotic products, health functional supplements, animal feed, and the like.

A problem to be solved by the present invention is to provide a uremic toxin reducing agent, a total cholesterol reducing agent and a triglyceride reducing agent. The problem is solved by providing a uremic toxin reducing agent, a total cholesterol reducing agent and a triglyceride reducing agent, wherein each agent comprises Lactobacillus bacteria, Bifidobacterium bacteria or Bacteroides bacteria.

Disclosed are a novel Lactobacillus fermentum) E4 strain isolated from Kimchi which is a traditional Korean fermented food and a mass production method for the strain. The Lactobacillus fermentum E4 strain is verified to be a safe and useful probiotic strain through acid tolerance, bile acid tolerance, gelatin liquefaction, and urease tests. In addition, high DPPH free radical scavenging (%) associated with antioxidant activity was observed, and reduction in cytokines Iinterleukin-1β (IL-1β), Iinterleukin-8 (IL-8), Iinterleukin-6 (IL-6), and Toll-like receptor (TLR4), which are associated with an inflammatory response, was observed.

Disclosed are a novel Lactobacillus fermentum) E4 strain isolated from Kimchi which is a traditional Korean fermented food and a mass production method for the strain. The Lactobacillus fermentum E4 strain is verified to be a safe and useful probiotic strain through acid tolerance, bile acid tolerance, gelatin liquefaction, and urease tests. In addition, high DPPH free radical scavenging (%) associated with antioxidant activity was observed, and reduction in cytokines Iinterleukin-1β (IL-1β), Iinterleukin-8 (IL-8), Iinterleukin-6 (IL-6), and Toll-like receptor (TLR4), which are associated with an inflammatory response, was observed.

An object of the present invention is to provide a method for efficiently obtaining a lactic acid bacterium that is made to contain a large amount of double-stranded RNA; and a lactic acid bacterium having a high double-stranded RNA content obtained by the method. The object is achieved by: (1) a method for producing a double-stranded RNA-containing lactic acid bacterium, including a step of culturing a lactic acid bacterium under at least one condition of an aeration condition and a low-temperature condition lower than an optimum temperature, thereby obtaining the double-stranded RNA-containing lactic acid bacterium; (2) a double-stranded RNA-containing lactic acid bacterium, in which the content of double-stranded RNA is 2.0 times or more as compared with the content of double-stranded RNA when a bacterium of the same strain is cultured for the same culture time under an optimum temperature and non-aeration condition; or the like.